Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

61 results about "Receptor potential" patented technology

A receptor potential, also known as a generator potential, a type of graded potential, is the transmembrane potential difference produced by activation of a sensory receptor. A receptor potential is often produced by sensory transduction. It is generally a depolarizing event resulting from inward current flow. The influx of current will often bring the membrane potential of the sensory receptor towards the threshold for triggering an action potential. Receptor potential can work to trigger an action potential either within the same neuron or on an adjacent cell. Within the same neuron, a receptor potential can cause local current to flow to a region capable of generating an action potential by opening voltage gated ion channels. A receptor potential can also cause the release of neurotransmitters from one cell that will act on another cell, generating an action potential in the second cell. The magnitude of the receptor potential determines the frequency with which action potentials are generated, and is controlled by adaption, stimulus strength, and temporal summation of successive receptor potentials. Receptor potential relies on receptor sensitivity which can adapt slowly, resulting in a slowly decaying receptor potential or rapidly, resulting in a quickly generated but shorter lasting receptor potential.

TRPV4 inhibition to treat arrhythmic cardiomyopathy

Genome sequencing identified a new gene associated with a cardiac arrhythmic disease, TAXI -binding protein 3. From cell line models and a conditional knock-out mouse models of the gene deletion, it was found that a specific molecule, transient receptor potential vanilloid 4 (TRPV4), is up-regulated and is associated with calcium mediated arrhythmic depolarizations.
Owner:DUKE UNIV

Compositions and methods for mode-selective modulation of transient receptor potential vanilloid-1 (TRPV1)

PCT designated stageWO2026006328A1Organic chemistryHeterocyclic compound active ingredientsSelective modulationClinical trial
TRPV1 is an integral cation channel widely expressed in various tissues and involved in critical biological functions, such as thermosensation. It is polymodally activated by distinct stimuli, including chemical ligands, heat, and protons (pH). However, dozens of clinical trials targeting various types of TRPV1 -mediated pain have generally failed, primarily due to hyperthermia (increased body temperature). Meta-analysis of clinical data suggests that mode-selectivity is essential to realizing the therapeutic potential of TRPV1. TRPV1 is regulated allosterically, with vanilloids and other chemical ligands binding to the voltage-sensing-like domain (VSLD), resulting in the gating of the pore domain. Therefore, compositions and methods for modulating TRPV1 to treat human pathophysiologies, such as pain, are described herein.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA +1

Active agent modulating the activity of an ion channel for use in regulation of skin pigmentation

Active agents are used for actively controlling and / or treating skin pigmentation in subjects without undesired side effects by activating, enhancing, inactivating, blocking or dampening the cellular response of the transient receptor potential ion channel TRPM5 or interfering with the expression of the ion channel.
Owner:CUTANEON SKIN & HAIR INNOVATIONS GMBH

Gel eye pad for treating xerophthalmia as well as preparation method and application of gel eye pad

The invention relates to the technical field of eye care products, in particular to a gel eye patch for treating xerophthalmia and a preparation method and application thereof.The preparation method comprises the steps that a gelatin solution, a carboxymethyl chitosan solution and a borneol solution are mixed, shaped and soaked, soaked gel is obtained, a gel matrix is placed on the soaked gel, the gel eye patch is obtained after soaking, and the gel eye patch is used for treating xerophthalmia. And soaking in a sodium sulfate solution for 30 minutes, and the mass percentage of the sodium sulfate solution is 15%. When the gel eye pad acts on the periphery of the eye, the borneol is combined with the transient receptor potential cation channel subfamily M member 8 on the ocular surface, so that the lacrimation is stimulated by activating the cold-sensitive primary afferent neuron. A layer of gel is added on the eye pad to prepare the double-layer gel eye pad. And the upper gel can be physically isolated, so that the irritation of the volatility of borneol to eyes is avoided. The traditional Chinese medicine composition can safely, quickly and effectively promote tear secretion of a patient suffering from the xerophthalmia, and irritation is effectively avoided while the xerophthalmia is treated.
Owner:FUJIAN BOCAOHUI PHARMACEUTICAL GROUP CO LTD

Oral nicotine composition and product thereof

Embodiments of the present invention provide an oral nicotine composition and a product thereof, the oral nicotine composition comprising: a nicotine component, an active component that can be used to block nicotinic acetylcholine receptor and / or transient receptor potential ion channels, and lecithin, the lecithin is matched with the active component which can be used for blocking a nicotine acetylcholine receptor and / or transient receptor potential ion channel, so that nicotine stimulation, especially stomach stimulation, can be effectively relieved, and discomfort symptoms such as heartburn, hiccup and stomachache of a user are avoided.
Owner:SHENZHEN HUABAO COLLABORATIVE INNOVATION TECH RES INST CO LTD

Five-membered 3-aryloxyl-3-heteroaryl propylamine compound, and crystalline form and use thereof

UndeterminedES3075814T3ArylDisease
The present invention relates to a five-membered 3-aryloxy-3-heteroarylpropylamine compound, its crystalline form, and its use. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt or prodrug thereof, having the structure of Formula I. The compound, or the pharmaceutically acceptable salt or prodrug of the present invention, possesses excellent inhibitory function against the transient receptor potential (TPR) channel protein and good therapeutic function for TPR-associated diseases.
Owner:SHANGHAI LEADO PHARMATECH CO LTD (100 00)

Compounds for treatment of excitotoxicity

PCT designated stageWO2026060489A1Nervous disorderOrganic chemistrySensory potentialTRPC
The present invention relates to modulators of canonical-type of transient receptor potential (TRPC) channels, compositions thereof, and methods therewith. The present invention also relates to methods of treating TRPC mediated conditions using such modulators.
Owner:NYRADA PTY LTD

3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives as TRPA1 inhibitors

The present disclosure provides certain 3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
Owner:BOEHRINGER INGELHEIM INT GMBH

Application of multiple promoters capable of efficiently targeting on ON-type bipolar cells in gene therapy technology

The invention relates to the technical field of biology and the technical field of gene therapy. The invention relates to a retina light-donating bipolar cell specific promoter sequence and application thereof to regulation and control of expression of therapeutic genes in retina or retina organoid cells in a gene therapy technology so as to improve and / or recover vision. The retina bipolar cells are divided into light-supplying activated bipolar cells (ON type bipolar cells or depolarized bipolar cells) and light-removing activated bipolar cells (OFF type bipolar cells or hyperpolarized bipolar cells), and accurate and specific expression of transgenosis is realized by utilizing gene differential expression characteristics of different types of bipolar cells. The efficient and accurate treatment on the retina diseases is realized. The promoter has the advantage that the promoter of the transient receptor potential cation channel protein (TRPM1) gene with high-level and high-specificity expression can be realized in light-activated bipolar cells.
Owner:ZHONGMOU MEDICAL TECH (WUHAN) CO LTD

Polypeptide for treating Parkinson's disease

The invention discloses a polypeptide for treating Parkinson's disease. In the application, it is found for the first time that a transient receptor potential M2 type (TRPM2) channel is expressed more in a fragile DA neuron subgroup, the expression quantity of the TRPM2 channel is positively correlated with age in a Parkinson's disease (PD) patient, and an action mechanism is defined through strict experiments, that is, the TRPM2 channel is preferentially activated in an ADE neuron through a PARP-1 / PARG / ADPR axis to drive Mfn2 / Bcl-2 complex-dependent mitochondrial hyper-fusion, so that the expression quantity of the TRPM2 channel is positively correlated with age; the ADE neuron death is caused. In addition, the TRPM2 channel also mediates the susceptibility of SNc DA neurons in the mouse treated by MPTP through Mfn2 / Bcl-2. It is found for the first time that blocking of PARP-1 / PARG / ADPR and Mfn2 / Bcl-2 mediated DA neuron death pathways can prevent DA neuron death of a specific induced pluripotent stem cell (iPSC) source of a patient suffering from the spontaneous Parkinson's disease (SPD). As susceptible SNc DA neuron loss is a main symptom of PD, PARP-1 / PARG / ADPR and Mfn2 / Bcl-2 pathways may become new therapeutic targets for PD.
Owner:ZHEJIANG UNIV

3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof

Disclosed are a 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof. Specifically disclosed is a compound or a pharmacologically acceptable salt thereof or a prodrug thereof. The compound has the structure of formula I. The compound or the pharmacologically acceptable salt thereof or the prodrug thereof has excellent inhibition to transient receptor potential (TPR) channel proteins, and has good therapeutic effect on diseases related to the TPR channel proteins.
Owner:SHANGHAI LEADO PHARMATECH CO LTD

Application of anacycline A in preparation of analgesic drugs

The invention relates to application of anacycline A in preparation of analgesic drugs, in particular to an anacycline A compound separated from anacycline roots. The compound can be applied to analgesic drugs with inhibition effects on transient receptor potential cation channel subfamily M member 8 (TRPM8), a voltage-gated potassium ion channel 1.2 (Kv1.2), a voltage-gated potassium ion channel 1.3 (Kv1.3), transient receptor potential cation channel protein 6 (TRPC6) and a voltage-gated calcium ion channel 2.1 (Cav2.1), in particular to drugs for neuropathic pain, traumatic pain or inflammatory pain. The compound anacycline A can be combined with a plurality of analgesia-related targets, so that a synergistic effect is generated, the treatment effect is enhanced, and meanwhile, side effects and drug resistance are reduced.
Owner:XINJIANG TECH INST OF PHYSICS & CHEM CHINESE ACAD OF SCI +1

Artificial retina and method for producing same

There is provided an artificial retina in which an organic dye compound is fixed onto a thin sheet, wherein the organic dye compound induces a receptor potential responding to photostimulation; the thin sheet is formed by connecting microfibers having an average fiber diameter of 2 to 1,000 nm to each other to form a porous structure; and the porous structure makes the artificial retina liquid-permeable. Thus, there is provided an artificial retina that can induce a receptor potential responding to photostimulation with high sensitivity and is liquid-permeable and therefore has improved biocompatibility.
Owner:UNIV OKAYAMA

3-aryloxy-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof

A 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof are provided. Specifically, a compound, or a pharmaceutically acceptable salt or a prodrug thereof, the compound having a structure of formula I is described. The compound, or pharmaceutically acceptable salt or prodrug thereof has an excellent inhibition function for a transient receptor potential channel protein (TPR), and has a good treatment function for diseases associated with the TPR.
Owner:SHANGHAI LEADO PHARMATECH CO LTD

Oral antagonist compositions for nicotine burning relief

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents, and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and / or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a third antagonist comprising (1R,2S,5R)—N-(4-Methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12).
Owner:FERTIN PHARMA AS

Riboswitches for regulating gene expression and therapeutic methods of using the same

PCT designated stage expiredWO2024227074A9VectorsPeptide/protein ingredientsHeterologousEnzyme Gene
The present disclosure provides an expression cassette comprising from 5' to 3': (i) promoter, (ii) an upstream exon, (iii) an upstream intron, (iv) an alternatively spliced exon comprising a translation initiation sequence, (v) a downstream intron, (vi) a downstream exon, and (vii) a heterologous nucleic acid sequence. In some aspects, the upstream exon, the upstream intron, the alternatively spliced exon, the downstream intron, and the downstream exon, each comprise a portion of a gene selected from the group consisting of a Transient Receptor Potential Cation Channel Subfamily V Member 3 (TRPV3) gene, a Serine / Threonine Kinase 31 (STK31) gene, an Ubiquitin Specific Peptidase 25 (USP25) gene, a IK gene, a Testis Expressed 14, Intercellular Bridge Forming Factor (TEX14) gene, a General Transcription Factor IIB (GTF2B) gene, and a LY6 / PLAUR Domain Containing 3 (LYPD3) gene.
Owner:KRIYA THERAPEUTICS INC

A transient receptor potential cation channel TRPV3 inhibitor and its use

The present invention belongs to the field of medical technology, and specifically relates to a transient receptor potential cation channel TRPV3 inhibitor and its use. The present invention provides a class of compounds that can be used as TRPV3 inhibitors, which can inhibit the abnormal increase in calcium ion influx caused by TRPV3 activation, can effectively treat and prevent TRPV3-related diseases, and provide new ideas for diseases such as itching, hair loss, atopic dermatitis, psoriasis, ulcerative colitis, etc. The compounds provided by the present invention have better solubility, inhibit epidermal thickening, improve psoriasis symptoms, and show good pharmacodynamic effects.
Owner:SUZHONG PHARMACEUTICAL GROUP CO LTD +1

Treatment for hot flushes

PendingUS20250186375A1Pharmaceutical delivery mechanismAmide active ingredientsTransient receptor potential channelChannel blocker
Disclosed herein are methods for treating hot flushes in a subject. In one embodiment, treating hot flushes includes administering to a subject in need of such treatment, a therapeutically effective amount of a transient receptor potential channel (TRP channel) blocker or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for amelioration, alleviation, or prevention of the thermal discomfort in hot flushes, comprising: selecting a subject in need of treatment for hot flushes, administering to the subject a therapeutically effective amount of a TRP channel blocker, such as a TRPV1 blocker, or a pharmaceutically acceptable salt thereof.
Owner:DIGNITY HEALTH

Transient receptor potential vanilloid 6 inhibitors

The present invention relates to methods and uses of preventing or treating cancer The method or use may comprise administration of a cancer therapy together with a compound of Formula (I). In the compound of Formula (I) A is a substituted heteroaryl comprising at least one ring nitrogen; and D includes an optionally substituted: phenyl, N-linked 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, N-linked 10H-phenoxazinyl, indole, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl or thienyl (or R3' and D together form a five or six membered ring). The compound of Formula (I) may be an inhibitor of transient receptor potential vanilloid 6 (TRPV6). The cancer therapy may be a chemotherapeutic agent. The present invention also relates to pharmaceutical compositions and kits comprising a compound of Formula (I) and / or a chemotherapeutic agent.
Owner:UNIQUEST PTY LTD

Application of alkylamine compound

PendingCN121818599ANervous disorderAntipyreticTransient receptor potential channelPharmaceutical drug
The invention relates to application of alkylamine compounds. Specifically, the invention provides an application of a compound shown as a formula I, or an optical isomer thereof, or a raceme thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, the compound, or the optical isomer thereof, or the raceme thereof, or the solvate thereof, or the pharmaceutically acceptable salt thereof are used for preparing a pharmaceutical composition or a preparation, and the pharmaceutical composition or the preparation is used for (a) inhibiting transient receptor potential channel protein; (b) treating diseases related to transient receptor potential channel protein, in the formula, each group is defined as in the specification. (I).
Owner:NINGBO LIDAO PHARMACEUTICAL TECHNOLOGY CO LTD

Active agents that modulate the activity of ion channels for use in modulating skin pigmentation - Patents.com

In order to provide novel active agents for actively controlling and / or treating skin pigmentation in a subject without undesirable side effects, the present invention discloses active agents that activate, enhance, inactivate, block or attenuate the cellular response of the transient receptor potential ion channel TRPM5 or interfere with the expression of said ion channel.
Owner:MONASTERIUM LAB SKIN & HAIR RES SOLUTIONS GMBH

Compositions and Methods for Treating Cardiovascular Diseases and Disorders

Disclosed herein are compounds and ligands, and compositions formed therewith, that treat insulin resistance-induced physiological disorders by modulating G-protein coupled receptor (GPCR) and transient receptor potential (TRP) ion channel activity. Also disclosed herein are methods for using the compositions to treat cardiovascular disorders, such as atherosclerosis.
Owner:OLFACTIVE AI INC

Preparation method for and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound

ActiveUS12492195B2AntipyreticAnalgesicsArylTransient receptor potential channel
Provided are a compound as represented by formula I, a preparation method therefor, and a hydrochloride crystal form A thereof. The compound as represented by formula I and the hydrochloride crystal form A thereof have excellent inhibitory effects on transient receptor potential (TRP) channels, and have good therapeutic effects on TRP channel-associated diseases.
Owner:ZHANGZHOU PIEN TZE HUANG PHARM +1

Transient receptor potential vanilloid 6 inhibitors

The present invention relates to a method for preventing or treating cancer and its use therefor. The method or use may include administering a cancer therapy together with a compound of Formula (I). In the compound of Formula (I), A is a substituted heteroaryl containing at least one ring nitrogen, and D includes optionally substituted phenyl, N-linked 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, N-linked 10H-phenoxazinyl, indole, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, or thienyl (or R3' and D together form a 5- or 6-membered ring). The compound of Formula (I) may be an inhibitor of transient receptor potential vanilloid 6 (TRPV6). The cancer therapy may be a chemotherapeutic agent. The present invention also relates to pharmaceutical compositions and kits containing the compound of Formula (I) and / or a chemotherapeutic agent. TIFF2026502807000127.tif30170
Owner:UNIQUEST PTY LTD

Treatment and prevention of trigeminal neuralgia

The present disclosure provides methods of treating and preventing trigeminal nerve pain with modulators of oxidative stress (e.g., NRF2 transcription network activators and / or inhibitors of transient receptor potential ankyrin 1 (TRPA1)) and compositions thereof.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1